Form S-4
TEVA PHARMACEUTICAL INDUSTRIES LTD filed this Form S-4 on 04/02/2018
Document Outline
Entire Document (1495.5 KB)
Subdocument 1 - S-4 - FORM S-4
Page 1 - As filed with the Securities and Exchange Commission on April 2, 2018
Page 2 - Schedule A
Page 3 - The information in this prospectus is not complete and may be changed. We may not sell these securit
Page 4 - You should rely only on the information contained in this prospectus. We have not authorized anyone
Page 5 - WHERE YOU CAN FIND MORE INFORMATION
Page 6 - INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
Page 7 - FORWARD-LOOKING STATEMENTS
Page 8 - N/A
Page 9 - PROSPECTUS SUMMARY
Page 10 - http://www.tevapharm.com
Page 11 - N/A
Page 12 - The Exchange Offer
Page 13 - N/A
Page 14 - N/A
Page 15 - Consequences of Not Exchanging Original Notes
Page 16 - Terms of the Exchange Notes
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - RATIO OF EARNINGS TO FIXED CHARGES
Page 21 - RISK FACTORS
Page 22 - A downgrade, suspension or withdrawal of the rating assigned by a rating agency to the Exchange Note
Page 23 - The guarantees will effectively be subordinated to some of our existing and future indebtedness.
Page 24 - Teva may be subject to restrictions on receiving dividends and other payments from its subsidiaries.
Page 25 - The Exchange Notes have minimum specified denominations of $200,000 (in case of the Exchange Dollar
Page 26 - If the exchange offer is not completed within a certain period after the issuance date of the respec
Page 27 - USE OF PROCEEDS
Page 28 - EXCHANGE OFFER
Page 29 - Terms of the Exchange Offer; Period for Tendering Outstanding Original Notes
Page 30 - Procedures for Tendering Original Notes Through Brokers and Banks
Page 31 - BY TENDERING YOUR ORIGINAL NOTES YOU ARE DEEMED TO HAVE MADE THESE REPRESENTATIONS.
Page 32 - Procedures for Brokers and Custodian Banks; DTC ATOP Account
Page 33 - N/A
Page 34 - Book-Entry Transfer
Page 35 - Acceptance of Outstanding Original Notes for Exchange; Delivery of Exchange Notes
Page 36 - N/A
Page 37 - Exchange Agent
Page 38 - Accounting Treatment
Page 39 - N/A
Page 40 - DESCRIPTION OF THE EXCHANGE DOLLAR NOTES
Page 41 - Description of the Guarantees
Page 42 - Payment of Interest and Principal
Page 43 - N/A
Page 44 - Certain Covenants
Page 45 - Limitations on Sales and Leasebacks
Page 46 - Tax Redemption
Page 47 - Events of Default
Page 48 - Consolidation, Merger or Assumption
Page 49 - Modifications and Amendments
Page 50 - Satisfaction and Discharge
Page 51 - DESCRIPTION OF THE EXCHANGE EURO NOTES
Page 52 - Description of the Guarantees
Page 53 - Payment of Interest and Principal
Page 54 - N/A
Page 55 - Certain Covenants
Page 56 - Certain Other Covenants
Page 57 - Tax Redemption
Page 58 - Events of Default
Page 59 - Consolidation, Merger or Assumption
Page 60 - Modifications and Amendments
Page 61 - Satisfaction and Discharge
Page 62 - CERTAIN TAX CONSIDERATIONS
Page 63 - own tax advisor as to particular tax consequences to it of exchanging Original Notes for Exchange No
Page 64 - Holders who do not exchange their Original Notes for Exchange Notes
Page 65 - Certain Israeli Tax Considerations
Page 66 - Original Issue Discount
Page 67 - PLAN OF DISTRIBUTION
Page 68 - LEGAL MATTERS
Page 69 - EXPERTS
Page 70 - Teva Pharmaceutical Finance Netherlands III B.V.
Page 71 - PART II
Page 72 - N/A
Page 73 - Teva Pharmaceutical Finance Netherlands II B.V. and Teva Pharmaceutical Finance Netherlands III B.V.
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - SIGNATURES
Page 84 - N/A
Page 85 - SIGNATURES
Page 86 - SIGNATURES
Subdocument 2 - EX-3.4 - EX-3.4
Page 1 - Exhibit 3.4
Page 2 - NOTE ABOUT TRANSLATION:
Page 3 - Final statements.
Page 4 - NOTE ABOUT TRANSLATION:
Page 5 - Final statements.
Page 6 - Continuous text as per November 14, 2013
Page 7 - Share ownership.
Page 8 - Share certificates.
Page 9 - Payment on shares.
Page 10 - Pledge.
Page 11 - Representation.
Page 12 - Adoption of the financial statements; discharge; publication.
Page 13 - General meeting.
Page 14 - Depositary receipts for shares.
Page 15 - Decision-making.
Page 16 - Amendment to these Articles of Association and winding up.
Page 17 - Disputes procedure.
Subdocument 3 - EX-3.5 - EX-3.5
Page 1 - Exhibit 3.5
Page 2 - SHARE CAPITAL.
Page 3 - SHAREHOLDERS REGISTER.
Page 4 - SHARE CERTIFICATES.
Page 5 - SHARES HELD BY THE COMPANY IN ITS OWN CAPITAL.
Page 6 - SHARE TRANSFER RESTRICTIONS.
Page 7 - REPRESENTATION.
Page 8 - ADOPTION OF THE FINANCIAL STATEMENTS; DISCHARGE; PUBLICATION.
Page 9 - GENERAL MEETING.
Page 10 - DEPOSITARY RECEIPTS FOR SHARES.
Page 11 - DECISION-MAKING.
Page 12 - AMENDMENT TO THESE ARTICLES OF ASSOCIATION AND WINDING UP.
Page 13 - OTHER POWERS.
Subdocument 4 - EX-3.6 - EX-3.6
Page 1 - Exhibit 3.6
Page 2 - CHAPTER II.
Page 3 - CHAPTER III.
Page 4 - Article 8. Payment on shares.
Page 5 - CHAPTER IV.
Page 6 - Article 16 Appointment Suspension and removal from office Remuneration.
Page 7 - Article 19. Approval of resolutions of the management board.
Page 8 - Article 22. Profit.
Page 9 - CHAPTER VIII.
Page 10 - Article 24. Depositary receipts for shares.
Page 11 - Article 28. Decision-making without a meeting being held.
Page 12 - Article 30. Liquidation.
Page 13 - Teva Pharmaceuticals Europe B.V.,
Subdocument 5 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Page 3 - N/A
Subdocument 6 - EX-5.2 - EX-5.2
Page 1 - Exhibit 5.2
Page 2 - page
Page 3 - page
Page 4 - page
Page 5 - page
Page 6 - page
Page 7 - page
Subdocument 7 - EX-5.3 - EX-5.3
Page 1 - Exhibit 5.3
Page 2 - Teva
Page 3 - N/A
Subdocument 8 - EX-12.1 - EX-12.1
Page 1 - Exhibit 12.1
Subdocument 9 - EX-21.0 - EX-21.0
Page 1 - Exhibit 21.0
Subdocument 10 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Subdocument 11 - EX-25.1 - EX-25.1
Page 1 - Exhibit 25.1
Page 2 - If the obligor is an affiliate of the trustee, describe each such affiliation.
Page 3 - N/A
Page 4 - N/A
Page 5 - EXHIBIT 7
Page 6 - N/A
Page 7 - N/A
Subdocument 12 - EX-25.2 - EX-25.2
Page 1 - Exhibit 25.2
Page 2 - If the obligor is an affiliate of the trustee, describe each such affiliation.
Page 3 - N/A
Page 4 - N/A
Page 5 - EXHIBIT 7
Page 6 - N/A
Page 7 - N/A
Subdocument 13 - EX-99.1 - EX-99.1
Page 1 - Exhibit 99.1
Page 2 - N/A
Page 3 - Because all of the 2022 Original Euro Notes are held in book-entry accounts maintained by the Exchan
Subdocument 14 - EX-99.2 - EX-99.2
Page 1 - Exhibit 99.2
Page 2 - N/A
Page 3 - Because all of the 2025 Original Euro Notes are held in book-entry accounts maintained by the Exchan
Subdocument 15 - EX-99.3 - EX-99.3
Page 1 - Exhibit 99.3
Page 2 - N/A
Subdocument 16 - EX-99.4 - EX-99.4
Page 1 - Exhibit 99.4
Page 2 - N/A